Source comparison
CJC-1295 No DAC vs Sermorelin: Which Is Better?
The peptide research space treats CJC-1295 no DAC and Sermorelin as interchangeable GHRH analogs. They're not. CJC-1295 no DAC (also called Modified GRF 1-29) sustains elevated growth hormone release for 30 minutes post-injection through its 30-minute plasma h
This comparison does not assign a generated winner or score.
- The peptide research space treats CJC-1295 no DAC and Sermorelin as interchangeable GHRH analogs. They're not. CJC-1295 no DAC (also called Modified GRF 1-29) sustains elevated growth hormone release for 30 minutes post-injection through its 30-minute plasma half-life, creating a sustained pulse. Sermorelin (GRF 1-29), with a half-life under 10 minutes, produces a sharp GH spike that mirrors the body's natural ultradian rhythm but clears rapidly. Both stimulate the anterior pituitary's somatotroph cells to secrete endogenous GH. But the kinetics, dosing flexibility, and experimental applications differ substantially. We've worked with research teams comparing these compounds across aging models, metabolic studies, and recovery protocols. The compound you choose determines whether your data reflects sustained anabolic signaling or acute pulsatile response.
- What's the difference between CJC-1295 no DAC and Sermorelin in research applications?
- CJC-1295 no DAC (Modified GRF 1-29) has a plasma half-life of approximately 30 minutes, allowing for extended growth hormone secretion windows ideal for studying sustained anabolic effects. Sermorelin (GRF 1-29) clears within 8–10 minutes, producing sharp GH peaks that replicate natural pulsatile patterns. CJC-1295 no DAC is typically dosed at 100–200 mcg per administration, while Sermorelin ranges from 200–500 mcg due to its rapid clearance. Both require reconstitution with bacteriostatic water and refrigerated storage at 2–8°C post-mixing.
- The direct answer: these aren't functionally identical peptides with different labels. CJC-1295 no DAC was engineered specifically to resist dipeptidyl peptidase-IV (DPP-IV) enzymatic degradation. The addition of four amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) extends its half-life from under 10 minutes to roughly 30 minutes. Sermorelin retains the original GRF 1-29 structure with no modifications, making it highly susceptible to DPP-IV cleavage the moment it enters circulation. This structural difference means CJC-1295 no DAC delivers a longer GH elevation window per dose, while Sermorelin requires higher dosing or more frequent administration to achieve comparable AUC (area under the curve) exposure. This article covers the receptor-level mechanisms both compounds share, the pharmacokinetic distinctions that separate them, the dosing protocols research teams use for each, and the experimental contexts where one compound consistently outperforms the other.